Corneal Collagen Crosslinking and Intacs for Keratoconus and Ectasia

Keratoconus Clinical Trial

— CXL  

Official title:

Randomized Study of Safety and Effectiveness of Corneal Collagen Crosslinking and Intacs for Treatment of Keratoconus and Corneal Ectasia

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01112072
• Other study ID #: CLEI-Intacs-CXL
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: April 2010
• Est. completion date: December 2025

Study information

• Verified date: February 2023
• Source: Cornea and Laser Eye Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will determine the efficacy of corneal collagen crosslinking (CXL) combined with Intacs for the treatment of keratoconus and corneal ectasia. The goal of CXL is to decrease the progression of keratoconus, while Intacs has been shown to decrease corneal steepness in keratoconus. This study will attempt to determine the relative efficacy of the two procedures either performed at the same session versus CXL performed 3 months after Intacs.

Description:

The purpose of this is to ascertain the possible additive effect of the two treatments to both improve the quality of the corneal optics (i.e. improve corneal topography regularity) and to stabilize the cornea. Previous investigations have shown that Intacs surgery, indeed, does improve corneal topography and improve contact lens tolerance and spectacle corrected visual acuity, as well as uncorrected visual acuity in some patients. Investigations of CXL have shown the procedure not only to decrease keratoconus progression, but also to decrease the steepness of the cone and improve uncorrected and best corrected visual acuity in some cases. Since the mechanism of improvement differs between the procedures, this suggests a potential additive effect of the two on the patient's ultimate visual outcome. Thus, the patient would be afforded two potential benefits: (1) the potential of a more robust visual outcome and (2) stabilization of the keratoconic cornea on the longer term.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 160
• Est. completion date: December 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• 21 years of age or older

• Having a diagnosis of keratoconus or corneal ectasia after corneal refractive surgery (e.g., LASIK, photorefractive keratectomy [PRK], or epi-LASIK)

• Subjects who meet the manufacturer's nomogram recommendations for Intacs segments

• Topography consistent with keratoconus or post-surgical corneal ectasia.

• BSCVA worse than 20/20 (<55 letters on ETDRS chart)

Exclusion Criteria:

• Eyes classified as either normal, atypical normal, or keratoconus suspect on the severity grading scheme.

• Corneal pachymetry = 400 microns at the thinnest point measured by Pentacam in the eye(s) to be treated when the isotonic riboflavin solution is used or = 300 microns when the hypotonic riboflavin us used, provided that the corneal thickness after treatment with the hypotonic riboflavin solution is > 400 microns. Corneal pachymetry = 450 microns at the proposed insertion site for the Intacs

• Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications

• History of corneal disease

• History of chemical injury or delayed epithelial healing in the eye(s) to be treated.

• Pregnancy (including plan to become pregnant) or lactation during the course of the study

• A known sensitivity to study medications

• Subjects with nystagmus or any other condition that would prevent a steady gaze during the CXL and Intacs treatment or other diagnostic tests.

• Subjects with a current condition that, in the investigator's opinion, would interfere with or prolong epithelial healing.

Related Conditions & MeSH terms

• Corneal Diseases
• Corneal Ectasia
• Keratoconus

Intervention

Drug:
• Riboflavin
Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.

Locations

Country	Name	City	State
United States	Cornea and Laser Eye Institute	Teaneck	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Cornea and Laser Eye Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum keratometry		1 year
Secondary	Best Corrected Visual Acuity		1 year